You're contacting media contact of this press release

Title: New TIPS Study Shows IV Iron is Safe, Effective, and Well-Tolerated for Pregnant Women

Miami, FL — Jan 13th, 2025 — FEM Women’s Health (formerly known as Heme On Call) and GNP Research today announced results from the TIPS Study, the largest real-world evaluation of IV iron treatment in pregnant women in the United States. The findings—now presented at the American Society of Hematology (ASH) 67th Annual Meeting 2025, the leading global hematology conference — show that IV iron is safe, effective, and fast-acting treatment option for pregnant women with low iron levels or anemia.The study followed 2,225 pregnant women who received IV iron in community clinics. Treated for iron deficiency or iron deficiency anemia (IDA), conditions that often cause fatigue, shortness of breath, and odd cravings during pregnancy. Across nearly 5,000 IV iron infusions, the research showed that IV iron is well-tolerated and provides rapid improvement in symptoms and blood counts.What the Study FoundWomen with anemia saw an average of +1.2-point ride in hemoglobinMore than 80% of women reported feeling better, including more energy, reduced shortness of breath, and fewer cravings like ice chewingSerious reactions were rare, occurring in only 3.3% of all infusionsFewer discomfort symptoms with high-dose formulations, particularly Monoferric (ferric derisomaltose) (7.8%) and Feraheme (ferumoxytol) (15.2%), compared with Venofer (iron sucrose) (22.2%)Fewer total visits are required with high-dose IV iron, improving treatment completion and patient convenience“These findings show that when iron deficiency is recognized and treated promptly, IV iron provides fast, reliable improvement in maternal well-being without compromising safety” said Dr. Steven Fein, CEO of FEM Women’s Health.Why This Matters for PregnancyIron deficiency during pregnancy is common, yet many wo...

This press release is issued by King Newswire